☰

Zejula (Niraparib) Clinical Trials (November 2026): 37 Recruiting Interventional Studies in Ovarian Maintenance, Newly-Diagnosed MGMT-Unmethylated Glioblastoma, and Cross-Cancer PARP Combinations

Last updated: November 3, 2026

Drug profile:

Zejula (niraparib, MK-4827) is an oral, once-daily, selective PARP1/2 inhibitor originally discovered at Merck (MK-4827), licensed to Tesaro Inc. (which obtained the original FDA approval in 2017), and acquired by GSK (GlaxoSmithKline) through the Tesaro acquisition in December 2018. Janssen holds niraparib prostate cancer rights in certain territories. Zejula is FDA-approved for first-line ovarian cancer maintenance in HRD-positive disease (PRIMA, April 2020; originally approved regardless of biomarker status, restricted to HRD-positive in June 2025) and for recurrent ovarian maintenance in germline BRCA-mutated disease (NOVA, March 2017; restricted November 2022). Dosed once daily orally (200 mg or 300 mg starting dose, individualized by baseline body weight and platelet count).

Mechanism of action:

Niraparib selectively inhibits PARP1 and PARP2, two nuclear enzymes that mediate DNA single-strand break repair and the broader DNA damage response. By blocking PARP-mediated repair in tumors that already have defective homologous-recombination repair (BRCA1/2 mutations, HRD-positive tumors), niraparib exploits synthetic lethality: the cancer cell accumulates unrepairable DNA damage and undergoes apoptosis, while normal cells with intact HR repair are largely spared. Niraparib is also a PARP "trapper" — it stabilizes the PARP-DNA complex on chromatin, blocking replication forks — with intermediate trapping potency in the class (talazoparib > niraparib > olaparib ≈ rucaparib). See the PARP Inhibitors mechanism hub for the cross-drug class comparison.

Regulatory status:

FDA-approved in 2 active ovarian indications, both in epithelial ovarian, fallopian tube, or primary peritoneal cancer: first-line maintenance in HRD-positive (including BRCA-mutated) disease (PRIMA Phase 3 trial, approved April 29, 2020 regardless of biomarker status; restricted to HRD-positive in June 2025 at the FDA's request after the PRIMA final overall-survival analysis) and recurrent maintenance after platinum response in germline BRCA-mutated disease (NOVA Phase 3 trial, approved March 27, 2017; restricted to germline BRCA in November 2022 after the NOVA final overall-survival analysis). A third indication (October 23, 2019) for HRD-positive heavily-pretreated recurrent ovarian based on the QUADRA trial was voluntarily withdrawn in September 2022. Niraparib is also FDA-approved in prostate cancer as Akeega (niraparib + abiraterone acetate, Janssen) for BRCA-mutated mCRPC (August 2023) and BRCA2-mutated mCSPC (AMPLITUDE, December 2025).

Trial-link audit, November 13, 2026: cited IDs resolve in ClinicalTrials.gov. Selected phase and recruitment labels were corrected against registry records. Existing corpus totals retain their stated snapshot dates; confirm current site and cohort availability with the study team.

Why Zejula Matters — In Plain Language

PARP (poly ADP-ribose polymerase) is a family of enzymes that help cells repair single-strand breaks in DNA. PARP1 and PARP2 are the dominant cancer-relevant members. When PARP is inhibited, single-strand breaks persist and become double-strand breaks during the next round of DNA replication. Normal cells repair those double-strand breaks using the homologous recombination (HR) pathway — a high-fidelity repair system driven by BRCA1, BRCA2, PALB2, and the broader HRR gene panel. Cancers with defective HR (BRCA1/2 mutations, HRD-positive tumors) cannot accurately repair the double-strand breaks; they accumulate unrepairable damage and die. This is synthetic lethality — two individually survivable defects (PARP inhibition + HR deficiency) become lethal in combination.

Niraparib's ovarian label has narrowed over time. PRIMA (FDA April 2020) originally made niraparib the only PARP inhibitor approved for first-line ovarian maintenance regardless of BRCA or HRD status; PRIMA showed PFS benefit largest in HRD-positive disease. However, after the PRIMA final analysis including overall survival, the FDA concluded the benefit-risk was no longer favorable outside HRD-positive disease, and in June 2025 the indication was restricted to HRD-positive (including BRCA-mutated) ovarian cancer. The recurrent-maintenance NOVA indication was similarly restricted to germline BRCA-mutated patients in November 2022. HRD testing (e.g., Myriad MyChoice CDx) is therefore now central to first-line maintenance decisions.

Niraparib is also blood-brain-barrier-penetrant — documented in preclinical models and Phase 1/2 glioma studies — a pharmacology feature that distinguishes it within the PARP class. This BBB penetration is the rationale behind NCT06388733, the first PARP inhibitor Phase 3 in glioblastoma: niraparib vs temozolomide in newly-diagnosed MGMT-unmethylated GBM, the population that derives little benefit from TMZ because the MGMT enzyme actively repairs the DNA damage TMZ produces. If positive, the trial would replace temozolomide for a major newly-diagnosed GBM subgroup and expand the PARP class beyond ovarian / breast / mCRPC / pancreatic into brain tumors.

FDA-Approved Indications

Zejula has 2 active FDA approvals, both in epithelial ovarian, fallopian tube, or primary peritoneal cancer (each later restricted by biomarker), plus one withdrawn indication.

Active Indications (2)

1L Advanced Ovarian Cancer Maintenance, HRD-Positive (PRIMA)

Pivotal trial: PRIMA Phase 3 (NCT02655016) vs placebo · FDA: April 29, 2020 · Setting: First-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy · Biomarker: HRD-positive (including BRCA-mutated) — originally approved regardless of biomarker status; restricted to HRD-positive in June 2025 at the FDA's request after the PRIMA final analysis including overall survival.

Recurrent Ovarian Cancer Maintenance, Germline BRCA-Mutated (NOVA)

Pivotal trial: NOVA Phase 3 (NCT01847274) vs placebo · FDA: March 27, 2017 (initial approval, originally without a BRCA biomarker requirement) · Setting: Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy · Biomarker: deleterious or suspected deleterious germline BRCA mutation — restricted in November 2022 at the FDA's request after the NOVA final overall-survival analysis (OS HR 1.06 in the non-germline-BRCA cohort).

Withdrawn Indication (1)

HRD-Positive Heavily-Pretreated Recurrent Ovarian (QUADRA) — VOLUNTARILY WITHDRAWN SEPTEMBER 2022

Pivotal trial: QUADRA Phase 2 single-arm (NCT02354586) · Original FDA accelerated approval: October 23, 2019 · Setting: Late-line treatment (not maintenance) of HRD-positive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens · Voluntarily withdrawn in September 2022 by GSK (Dear Health Care Provider letter, September 14, 2022), in consultation with the FDA, given the uncontrolled single-arm QUADRA design and late-line PARP inhibitor overall-survival concerns. The withdrawal does not affect the NOVA or PRIMA maintenance approvals — it specifically removed the late-line, heavily-pretreated single-agent niraparib indication. Patients who responded to single-agent niraparib in this setting can continue treatment under their treating physician's clinical judgment, but new starts under the QUADRA label are no longer FDA-supported.

★ First-Line Maintenance: HRD Testing Now Decides Eligibility

In ovarian cancer, the first-line maintenance decision is made shortly after a patient completes platinum-based induction chemotherapy. In real clinical practice, many patients do not yet have their BRCA / HRD biomarker results at that moment — germline BRCA testing turnaround can be days to weeks, somatic / HRD testing on tumor tissue can take longer, and a meaningful fraction of patients have HRD-negative or unknown biomarker status when the maintenance question is on the table.

PRIMA originally made Zejula the only FDA-approved PARP inhibitor for 1L ovarian maintenance regardless of BRCA / HRD status (April 2020). In June 2025, at the FDA's request after the PRIMA final analysis including overall survival, the indication was restricted to HRD-positive (including BRCA-mutated) disease; the FDA concluded the benefit-risk was no longer favorable for non-HRD-positive patients, and new starts in HRD-negative disease are not recommended.

The other FDA-approved PARP inhibitors for 1L ovarian maintenance — Lynparza (olaparib) SOLO-1 (BRCA-mutated 1L monotherapy maintenance) and PAOLA-1 (olaparib + bevacizumab in HRD-positive 1L maintenance) — require BRCA or HRD biomarker positivity for FDA-approved use. For BRCA-mutated or HRD-positive 1L ovarian, multiple PARPi options apply; for HRD-negative 1L ovarian, no PARP inhibitor is currently FDA-approved for maintenance.

Zejula vs Other PARP Inhibitors in the Class

Four PARP inhibitors are FDA-approved. The class differs by indication breadth, biomarker requirements, dosing, and toxicity profile:

Recruiting Zejula Trials

Curated subset of recruiting interventional Zejula (niraparib) trials in the ClinTrialFinder corpus as of June 27, 2026 (approximately 37 recruiting interventional trials total). Trials are grouped by clinical setting and ordered by phase and clinical significance.

Phase 3 — Registrational and Cross-Cancer Headline Programs

Phase 2 — Ovarian Maintenance Optimization (1L and Recurrent)

Cross-Cancer Phase 1/2 — Beyond Ovarian (Brain, Pancreatic, Prostate, Breast, SCLC, Endometrial, Penile)

Niraparib is being studied across multiple cancer types based on either documented BBB penetration (brain), BRCA / HRR mutation status (cross-cancer), or PARP-relevant biomarker biology (SLFN11). None of these cross-cancer indications are FDA-approved for Zejula; separately, niraparib is FDA-approved in prostate cancer only as Akeega (niraparib + abiraterone acetate) for BRCA-mutated mCRPC (August 2023) and BRCA2-mutated mCSPC (December 2025).

Showing a curated subset of recruiting Zejula (niraparib) interventional trials in the ClinTrialFinder corpus as of June 27, 2026 (approximately 37 recruiting interventional trials total). For the latest list: view all recruiting niraparib trials on ClinicalTrials.gov.

Mechanism: PARP1/2 Inhibition + Synthetic Lethality, with BBB Penetration

Target: PARP1 and PARP2 (poly ADP-ribose polymerase 1 and 2) — nuclear enzymes that sense single-strand DNA breaks, recruit DNA-repair machinery, and contribute to base excision repair and the broader DNA damage response. Niraparib is selective for PARP1/2 within the larger 17-member PARP family.

Mechanism step-by-step: (1) Niraparib enters the cell (oral, well-absorbed, BBB-penetrant) and binds the catalytic site of PARP1 and PARP2. (2) Catalytic inhibition blocks PARP-mediated single-strand break repair — unrepaired single-strand breaks accumulate. (3) During the next round of DNA replication, unrepaired single-strand breaks become double-strand breaks at replication forks. (4) Niraparib also "traps" PARP on chromatin — it stabilizes the PARP-DNA complex on damaged DNA, physically blocking replication-fork progression and amplifying double-strand-break generation. PARP trapping potency: talazoparib > niraparib > olaparib ≈ rucaparib. (5) In cells with intact homologous recombination (HR) repair (normal cells), the double-strand breaks are repaired with high fidelity — the cell survives. (6) In cells with defective HR (BRCA1/2-mutated, HRD-positive), the double-strand breaks cannot be repaired accurately; the cell accumulates damage and undergoes apoptosis. This is synthetic lethality — PARP inhibition is individually survivable; HR deficiency is individually survivable; combination is lethal.

Dosing: Oral, once daily, starting dose individualized: 200 mg for patients under 77 kg or with baseline platelet count under 150,000/microliter; 300 mg for patients at or above 77 kg and at or above 150,000/microliter platelet count. This weight-and-platelet-based starting dose was added to the label after the original approval to reduce thrombocytopenia-driven dose interruptions. Continue maintenance until disease progression or unacceptable toxicity. By contrast, Lynparza (olaparib) is dosed twice daily (300 mg BID); Talzenna (talazoparib) is dosed once daily at much lower milligrams (1 mg daily); Rubraca (rucaparib) is dosed twice daily.

BBB penetration: Niraparib has documented blood-brain-barrier penetration in preclinical models and Phase 1/2 glioma studies — a distinguishing pharmacology feature in the PARP class. This is the rationale behind the NCT06388733 Phase 3 in newly-diagnosed MGMT-unmethylated GBM (the first PARP Phase 3 in glioma) and the NCT06258018 niraparib + TMZ Phase 1/2 in glioma, and the NCT05700721 niraparib + dostarlimab in brain metastases. See the PARP Inhibitors mechanism hub for the cross-drug class comparison.

Side Effects and Practical Considerations

⚠ Distinctive Niraparib Toxicity: Thrombocytopenia (Low Platelets)

Thrombocytopenia (low platelet count) is the most patient-noticeable and most dose-limiting niraparib toxicity, and is substantially more pronounced with niraparib than with olaparib or rucaparib. Approximately 30% of patients experience Grade 3 or higher thrombocytopenia, and a meaningful fraction of patients drop their platelet count below 100,000/microliter — particularly in the first 1 to 3 months of treatment. Severe thrombocytopenia raises the risk of bleeding (typically minor — nosebleeds, easy bruising — but can be major in severe cases) and is the most common reason for dose interruption, dose reduction, or treatment discontinuation.

The FDA label was revised after the original approval to recommend a weight-and-platelet-based starting dose: 200 mg daily for patients under 77 kg or with baseline platelets under 150,000/microliter; 300 mg daily for patients at or above both thresholds. This individualized starting dose substantially reduces dose-interruption rates from thrombocytopenia. Routine CBC monitoring is intensive in the first few months (weekly for the first month, then biweekly, then monthly), with platelet-driven dose modifications built into the label. Patients should report any unusual bruising, nosebleeds, gum bleeding, or other bleeding signs promptly.

Other Cytopenias: Anemia and Neutropenia

Anemia (low red blood cell count) is common with niraparib, frequently requires dose modification, and sometimes requires red-blood-cell transfusion. Fatigue from anemia is a major contributor to patient-reported quality of life on PARPi maintenance. Neutropenia (low white blood cell count) is less prominent with niraparib than with talazoparib but still common. Routine CBC monitoring catches both signals. Anemia and neutropenia, like thrombocytopenia, are most prominent in the first 1-3 months of dosing and tend to stabilize thereafter.

Distinctive Niraparib Signal: Hypertension and Tachycardia

Hypertension (elevated blood pressure) is a niraparib-specific safety signal relative to other PARP inhibitors — both systolic and diastolic blood pressure elevations are reported, including some Grade 3 events. Blood pressure monitoring is part of routine niraparib care, particularly in the first 2 months. Patients with pre-existing hypertension may need anti-hypertensive medication adjustments. Tachycardia (elevated heart rate) is also reported. Patients with cardiovascular comorbidities should discuss the niraparib hypertension and tachycardia signals with their oncologist and cardiologist before starting treatment.

Other Common Adverse Events

Recently Activated Phase 3 Trials (Jun 2026)

Phase 3 trials that began recruiting in June 2026:

Long-Term: Secondary Myelodysplasia / AML

Secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are rare but documented late effects of PARP inhibitor treatment, observed in long-term follow-up across the PARPi class. The risk is highest in patients with extensive prior cytotoxic chemotherapy exposure (and the relevant comparator population — recurrent ovarian patients with multiple prior platinum / taxane regimens — has elevated baseline risk independent of PARPi). The absolute risk over the typical maintenance course appears low based on available data, but long-term surveillance continues to characterize this signal across all approved PARPi. The risk-benefit conversation is part of the informed-consent discussion before treatment.

Frequently Asked Questions

What is Zejula (niraparib)?

Zejula is the brand name for niraparib (MK-4827), an oral, once-daily, selective PARP1/2 inhibitor developed originally by Merck (MK-4827), licensed to Tesaro Inc. (which obtained the original FDA approval), and acquired by GSK (GlaxoSmithKline) through the Tesaro acquisition in December 2018. Janssen holds prostate cancer rights to niraparib in certain territories. Niraparib selectively inhibits PARP1 and PARP2, two enzymes that participate in DNA single-strand break repair and the broader DNA damage response. By blocking PARP-mediated repair in tumors that already have homologous-recombination repair defects (BRCA1/2 mutations, HRD-positive tumors), niraparib exploits synthetic lethality — the cancer cell cannot repair accumulating DNA damage and undergoes apoptosis. Zejula is FDA-approved for first-line ovarian cancer maintenance in HRD-positive (including BRCA-mutated) disease (PRIMA, April 2020; restricted from all-comers in June 2025) and for recurrent ovarian cancer maintenance after platinum response in germline BRCA-mutated disease (NOVA, March 2017; restricted November 2022). A third indication (October 2019) for HRD-positive heavily-pretreated recurrent ovarian (QUADRA) was voluntarily withdrawn in September 2022. Niraparib is also FDA-approved in prostate cancer as Akeega (with abiraterone) for BRCA-mutated mCRPC (August 2023) and BRCA2-mutated mCSPC (December 2025). Niraparib's once-daily oral dosing (200 mg or 300 mg, individualized by baseline weight and platelet count) and documented blood-brain-barrier penetration distinguish it from other PARP inhibitors in the class.

Which patients qualify for Zejula?

Zejula is FDA-approved for adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer in two maintenance settings. First indication (PRIMA, FDA-approved April 29, 2020): first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy. Originally approved regardless of BRCA or HRD status, the indication was restricted in June 2025 to HRD-positive (including BRCA-mutated) disease at the FDA's request after the PRIMA final analysis including overall survival; new starts are not recommended for HRD-negative patients. Second indication (NOVA, FDA-approved March 27, 2017): maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy — restricted in November 2022 to patients with a deleterious or suspected deleterious germline BRCA mutation after the NOVA final overall-survival analysis. Zejula is given once daily orally, with the starting dose individualized to 200 mg or 300 mg based on baseline body weight (under 77 kg vs at or above 77 kg) and baseline platelet count (under 150,000/microliter vs at or above) — this weight-and-platelet-based starting dose was added to the FDA label after the original approval to reduce dose-interruption rates from thrombocytopenia. The previously-approved QUADRA indication (HRD-positive heavily-pretreated recurrent ovarian) was voluntarily withdrawn in September 2022.

How is Zejula different from Lynparza (olaparib)?

Zejula (niraparib, GSK) and Lynparza (olaparib, AstraZeneca/Merck) are both FDA-approved oral PARP inhibitors and both exploit synthetic lethality in HR-deficient cancers, but their regulatory footprints, dosing, and biomarker positioning are meaningfully different. Lynparza was the first PARP inhibitor approved by the FDA (December 2014) and has the broadest cross-cancer footprint among PARPi: BRCA-mutated advanced ovarian (2014), BRCA-mutated HER2-negative metastatic breast (OlympiAD, January 2018), gBRCA metastatic pancreatic maintenance (POLO, December 2019), and BRCA / HRR-mutated mCRPC (PROfound, May 2020; PROpel + abiraterone 1L mCRPC, May 2023). Zejula's footprint is concentrated in ovarian cancer: first-line ovarian maintenance in HRD-positive disease (PRIMA, April 2020; originally all-comers, restricted to HRD-positive in June 2025) and recurrent ovarian maintenance in germline BRCA-mutated disease (NOVA, March 2017; restricted November 2022). Practical sequencing for ovarian cancer: BRCA-mutated 1L (Lynparza SOLO-1, Lynparza + bevacizumab PAOLA-1, or Zejula PRIMA); HRD-positive 1L without BRCA (PAOLA-1 olaparib + bev or PRIMA niraparib); HRD-negative 1L (no FDA-approved PARP inhibitor maintenance option since the June 2025 PRIMA restriction); BRCA-mutated platinum-sensitive recurrent (SOLO-2 olaparib, or NOVA niraparib for germline BRCA). Dosing: niraparib is once daily (200 mg or 300 mg, individualized) vs olaparib twice daily (300 mg BID). Toxicity profiles differ: niraparib has a more pronounced thrombocytopenia signal (prompting the weight-and-platelet-based starting-dose label revision) and hypertension; olaparib has a more pronounced anemia signal and a slightly higher nausea signal. See the Lynparza drug page for the BRCA / HRR cross-cancer discussion.

Is Zejula being tested in glioblastoma?

Yes — Zejula (niraparib) has the first PARP inhibitor Phase 3 trial in glioblastoma. NCT06388733 is a Phase 3 trial of niraparib vs temozolomide in newly-diagnosed MGMT-unmethylated glioblastoma — the population that derives little benefit from temozolomide because MGMT (the methylguanine methyltransferase repair enzyme) actively undoes the DNA damage that temozolomide is designed to cause. The trial rationale is that MGMT-unmethylated tumors have an intact DNA-damage repair pathway that minimizes TMZ benefit but creates a synthetic-lethality opportunity for PARP inhibition. Niraparib was selected for this Phase 3 specifically because it has documented blood-brain-barrier (BBB) penetration in preclinical models and Phase 1/2 glioma studies — a distinguishing pharmacology feature among PARP inhibitors. If the Phase 3 is positive, it would be a paradigm-shifting result on two levels: first, it would replace temozolomide (the Stupp protocol standard since 2005) for a major newly-diagnosed GBM subgroup; second, it would expand the PARP inhibitor class beyond its current ovarian / BRCA-mutated breast / mCRPC / pancreatic footprint into brain tumors. A companion Phase 1/2 trial (NCT06258018) tests niraparib + temozolomide in glioma — an alternative combination strategy. Other niraparib brain-related studies include NCT05700721 (niraparib + dostarlimab in brain metastases from solid tumors). See the Glioblastoma trials page for the full GBM trial landscape.

What are the main side effects of Zejula?

Zejula's distinctive side-effect profile is dominated by hematologic toxicity, with thrombocytopenia (low platelets) as the most patient-noticeable and dose-limiting effect — substantially more pronounced with niraparib than with olaparib or rucaparib. Approximately 30% of patients experience Grade 3 or higher thrombocytopenia, and a meaningful fraction of patients drop their platelet count below 100,000/microliter, particularly in the first 1-3 months of treatment. The FDA label was revised after the original approval to recommend a weight-and-platelet-based starting dose (200 mg for patients under 77 kg or with baseline platelets under 150,000; 300 mg for patients at or above both thresholds) to reduce dose-interruption rates. Routine CBC monitoring is intensive in the first few months, with platelet-driven dose modifications built into the label. Other common adverse events: anemia (also frequently requires dose modification or transfusion), neutropenia (less prominent than with talazoparib but still common), fatigue, nausea, vomiting, constipation, decreased appetite, headache, and insomnia. A distinctive niraparib safety signal relative to other PARP inhibitors is hypertension — systolic and diastolic blood pressure elevations are reported, including some Grade 3 events, and blood pressure monitoring is part of routine care during niraparib treatment. Tachycardia is also reported. Long-term: secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are rare but documented PARP class-wide late effects in long-term follow-up, particularly in patients with extensive prior cytotoxic chemotherapy exposure. The PARP class also carries a pneumonitis signal and a small fetal-toxicity signal (contraception required). See the PARP Inhibitors mechanism hub for the class-wide safety discussion.

Find Zejula and PARP Inhibitor Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find Zejula (niraparib) and other PARP inhibitor trials based on your specific cancer type, BRCA1/2 status (germline or somatic), HRD score, prior PARPi exposure, and country.

Choose your diagnosis for trial matching